An observational study in Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 9 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by Memorial Sloan Kettering Cancer Center · Observational
The purpose of this study is to improve the communication skills of physicians who transition lymphoma cancer patients from the end of treatment to survivorship.
885 studies on the registry are indexed under Hodgkin Disease; 132 are open to participants now.
This study's enrollment of 314 is above the median of 130 across 119 observational studies indexed under Hodgkin Disease.
Browse Hodgkin Disease studies →Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,930 studies on the registry; 328 are open to participants now.
Of its 129 completed or terminated interventional studies of FDA-regulated products, 66 (51%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients:
Patients from each site will be recruited from their respective lymphoma services.
Physicians:
Physicians from each site will be recruited from their respective lymphoma services.
Physicians:
Patients of Physicians:
For part 1 - have scans indicating remission and completing planned chemotherapy and/or radiation therapy. The treating physician will determine that clinical remission has been achieved based on their best judgment.
For part 2 (longitudinal phase): - have new scans indicating remission and completing planned chemotherapy and/or radiation therapy. The treating physician will determine that clinical remission has been achieved based on their best judgment.
Exclusion Criteria:
Physicians:
Patients of Physicians:
For Part 2 ONLY (longitudinal phase):
The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site.
The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site.
impact on patient outcomes of targeted physician communication skills training
Time frame: 3 years
impact of a targeted CST intervention on the physicians
use of strategies, tasks and skills about transitioning lymphoma patients from the end of primary treatment to survivorship.
Time frame: 3 years
describe communication during doctor-patient visits during the patients' first three years of survivorship
(MSKCC and MD Anderson baseline data only) The study team will look for qualitative themes to better understand the content of these conversations and the need for survivorship care planning. Half of these recordings were with MSKCC patients and physicians and half were with MD Anderson patients and physicians.
Time frame: 3 years
Documents are hosted by the registry — open the source record to download them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center